GLP-1 Body Composition: Fat Loss, Muscle, and Visceral Fat Changes

Scale Weight Is Only Part of the Story

You step on the scale and see a number drop. That is good. But the number alone does not tell you what is actually changing in your body. You might be losing mostly fat. Or you might be losing a mix of fat and lean muscle tissue. Or you might be seeing mostly water loss. These differences matter enormously for how you look, how strong you feel, and your long-term metabolic health.

GLP-1 medications do something specific to body composition that is worth understanding: they preferentially reduce fat mass, and within fat mass, they appear to target visceral adiposity (the dangerous internal fat around organs) more aggressively than subcutaneous fat (the fat under your skin). This is clinically significant independent of what the scale says.

Here is what the research actually shows about body composition changes on GLP-1, and how to optimize your outcomes.

Fat Mass vs. Lean Mass: The 70-30 Split

When you lose weight on GLP-1, the breakdown of what you are actually losing is not 100% fat. Research from the STEP 1 (semaglutide)^[1] and SURMOUNT-1 (tirzepatide)^[2] clinical trials, the gold-standard studies for these medications, shows that approximately 70-75% of weight lost is fat mass, while 25-30% is lean mass (muscle and other metabolically active tissue).

This lean mass loss might sound alarming, but it is important to contextualize it. The same 70-30 split occurs with other weight loss methods, including traditional calorie restriction and surgical weight loss. It is a predictable consequence of creating a sustained calorie deficit. Your body mobilizes both fat and some lean tissue when energy demand exceeds intake.

The critical difference with GLP-1 is that this 70-30 proportion can be substantially improved with deliberate intervention. Resistance training and adequate protein intake can shift the ratio dramatically in favor of fat loss and lean mass preservation. Patients who prioritize strength training during GLP-1 treatment see measurably better body composition outcomes than those who do not.

This is not a limitation of the medication. This is a feature of how physiology works, and it is one of the most important reasons why medical weight loss coaching is included in your Transformation Health program from day one.

Visceral Fat vs. Subcutaneous Fat: Which One Really Matters

Not all fat is created equal. Your body stores fat in two main locations: under your skin (subcutaneous fat) and around your internal organs (visceral fat). The difference is not cosmetic. It is metabolic.

Visceral fat is metabolically active and inflammatory. It secretes hormones and cytokines that directly impair insulin signaling, increase inflammation, and accelerate the development of metabolic disease. High visceral fat is more strongly associated with insulin resistance, type 2 diabetes, cardiovascular disease, fatty liver disease, and metabolic syndrome than subcutaneous fat, even after accounting for total body weight.

Subcutaneous fat is more metabolically neutral. It is the fat you can pinch. It does not directly impair insulin signaling in the same way.

Here is what makes GLP-1 medications clinically remarkable: research including sub-analyses of the STEP 1^[3] and SURMOUNT-1 trials shows that GLP-1 medications preferentially reduce visceral adiposity. Patients on GLP-1 show significant reductions in visceral fat volume and waist circumference, often exceeding what you would expect from the total weight loss alone.

This is important because it means the metabolic benefit of GLP-1 treatment extends beyond simple weight loss. You are reducing the type of fat most strongly linked to metabolic disease, cardiovascular risk, and liver disease.

Measuring Body Composition: Beyond the Scale

The scale measures weight, not body composition. For example, if a person loses 20 pounds from GLP-1 and gains 5 pounds of muscle through resistance training, the scale might show only a 15-pound loss, even though the patient’s body composition improved dramatically (lost more fat, preserved more muscle). This is why some patients plateau on the scale while continuing to see visible body changes and feel stronger.

There are several ways to measure body composition. They vary in cost, accuracy, and accessibility.

DEXA Scan: The Gold Standard

A DEXA (dual-energy X-ray absorptiometry) scan is the most accurate and commonly used measurement of body composition. It measures fat mass, lean mass, and bone mineral density with excellent precision. A DEXA scan takes about 10 minutes, involves minimal radiation exposure (less than a chest X-ray), and is not uncomfortable.

DEXA scans are not routine for weight loss patients, but they are increasingly available at fitness centers, medical facilities, and university research labs. Some Transformation Health patients opt for a baseline DEXA before starting treatment and a follow-up DEXA after 6 months or a year to track body composition changes. This provides objective data on whether resistance training and nutrition are effectively preserving or building lean mass.

Cost varies by facility but typically ranges from $50 to $150 per scan.

Waist Circumference: The Practical Proxy

Waist circumference is a simple, practical, and evidence-backed proxy for visceral adiposity. You measure the circumference of your waist at the level of the navel, consistently, ideally at the same time of day and under the same conditions (after voiding, before eating).

Clinical cutoffs are:

• Men: <40 inches is the target threshold
• Women: <35 inches is the target threshold

Waist circumference above these thresholds is associated with increased metabolic risk, independent of BMI. The good news is that GLP-1 treatment consistently reduces waist circumference. Tracking your waist circumference every 2-4 weeks gives you a simple, free data point on visceral fat reduction.

Bioelectrical Impedance (BIA)

Consumer body composition scales and handheld devices use bioelectrical impedance to estimate body composition. They send a small electrical current through your body and measure how quickly it travels (muscle conducts electricity faster than fat). The device then estimates fat mass and lean mass.

BIA is convenient and affordable, but accuracy varies. These devices are sensitive to hydration status, which changes throughout the day and with diet. If you use a BIA scale, measure yourself consistently (same time of day, same hydration state) to track trends rather than relying on absolute values.

BodPod: Air Displacement Plethysmography

A BodPod is a pod-shaped chamber that measures body composition via air displacement. It is less common than DEXA and typically more expensive ($75-$150 per scan), but it provides accurate measurements and does not involve radiation.

Timeline: When Do Body Composition Changes Show Up?

Body composition changes lag behind scale weight changes. This is important to understand, because it means your progress is not always visible or measurable right away.

Here is a typical timeline:

Weeks 1-4: You see scale weight loss, primarily from fluid loss and reduced food volume in your digestive tract. Body composition changes are occurring but are not yet large enough to measure with consumer methods.

Weeks 4-12: Scale weight loss accelerates as you enter a sustained calorie deficit. Fat mass reduction becomes measurable. If you are not doing resistance training, you may lose lean mass along with fat. If you are doing resistance training with adequate protein, lean mass preservation improves significantly.

Months 3-6: Body composition changes become visible to the eye. Clothes fit differently. Your waist circumference may decrease noticeably. Visceral fat reduction is significant, often reducing cardiovascular risk and improving metabolic markers (blood glucose, triglycerides, liver enzymes) even if scale weight loss plateaus.

Months 6-12: Continued lean mass preservation through training. You may gain back a small amount of weight as you add muscle tissue, while continuing to lose fat. This is a positive sign that your body composition is improving even if the scale is not moving as dramatically.

Body Recomposition: Can You Gain Muscle While Losing Fat?

A question many patients ask: “Can I build muscle while on GLP-1?”

The honest answer is: probably not in the way you might be imagining.

Pure body recomposition (simultaneous, substantial fat loss and muscle gain) is possible but rare and difficult for most adults. It typically happens under very specific conditions: untrained individuals with high body fat, who start resistance training, eating adequate protein, and are in a modest calorie deficit. In those early stages, the beginner gains some muscle while losing fat.

But for most patients on GLP-1, the physiology is different. You are in a calorie deficit. Your body is in a catabolic state (breaking down tissue for energy). In this state, building significant new muscle is very difficult because muscle growth requires a surplus of amino acids and energy (an anabolic state).

This does not mean you cannot be strong or build strength. Resistance training while on GLP-1 definitely improves strength and muscle tone. But the primary goal is not to build new muscle mass, it is to preserve the lean mass you have. With resistance training and adequate protein, you can preserve 80-90% of your lean mass during a calorie deficit. Without these interventions, you might lose 50% or more of your weight loss as lean mass.

This is why medical weight loss coaching is critical. Your Transformation Health provider will guide you on whether resistance training, progressive overload, and high protein intake are appropriate for your goals and timeline.

Optimizing Your Body Composition: Three Evidence-Based Interventions

If body composition matters to you (and it should, because it affects metabolic health, strength, and how you feel), three things matter:

1. Resistance Training

Resistance training is the most effective single intervention for preserving lean mass during weight loss. Studies comparing patients on GLP-1 with and without resistance training show dramatically better lean mass preservation in the training group.

You do not need to be a bodybuilder. 2-3 sessions per week of progressive resistance training (weights, resistance bands, bodyweight exercises) is enough to send a clear signal to your body to preserve muscle during a calorie deficit.

Transformation Health includes personalized fitness programming in all programs. Your coach will help you start a training routine that is safe and aligned with your current fitness level.

Read more about resistance training on GLP-1 →

2. Adequate Protein Intake

Protein is the building block of muscle and the primary stimulus for muscle protein synthesis. During a calorie deficit on GLP-1, higher protein intake supports lean mass preservation.

The general recommendation is 1.2 to 1.6 grams of protein per kilogram of body weight per day if you are doing resistance training. For a 200-pound person, that is roughly 110-145 grams of protein per day.

GLP-1 medications reduce appetite, which can make it harder to eat enough protein. This is where the challenge lies. Your Transformation Health nutrition coach will help you structure your meals to hit protein targets without feeling uncomfortably full.

Read more about high-protein diets on GLP-1 →

3. Consistency and Time

Body composition changes take time. You cannot optimize lean mass preservation in 4 weeks. The research on resistance training and lean mass preservation involves 12-24 week intervention periods. If you want to see measurable improvements in body composition, commit to 3-6 months of consistent resistance training and nutrition.

Visceral Fat Reduction and Cardiovascular Health

The visceral fat reduction caused by GLP-1 medications has cardiovascular and metabolic significance beyond simple weight loss.^[4]

The SELECT trial, published in the New England Journal of Medicine in 2023, randomized 17,604 adults with overweight or obesity to receive either semaglutide or placebo. The primary finding was a 20% reduction in major cardiovascular events (heart attack, stroke, death from cardiovascular cause) in the semaglutide group.

Was this reduction solely due to weight loss? Probably not. Sub-analyses of the trial and related research suggest that GLP-1 medications have direct cardiovascular benefits independent of weight loss,^[5] including preferential visceral fat reduction, improved insulin sensitivity, reduced inflammation, and improved cardiovascular function.

This matters because it means the benefit of GLP-1 treatment is not just about how you look. It is about reducing metabolic disease risk in ways that the scale does not capture.

Read more about GLP-1 and cardiovascular health →

Waist-to-Height Ratio: A Simple Health Marker

Beyond waist circumference, waist-to-height ratio is a simple but powerful marker of metabolic health. You divide your waist circumference by your height (both in the same units). A waist-to-height ratio of <0.5 is associated with low metabolic risk. A ratio >0.6 is associated with significantly increased risk.

GLP-1 treatment consistently improves waist-to-height ratio. Combined with resistance training and adequate protein, the improvements are even more dramatic.

You can track this at home with a measuring tape and calculator. No expensive equipment needed.

The Bottom Line: What Body Composition Data Actually Shows

Here is what we know from research and clinical experience:

1. Approximately 70-75% of weight lost on GLP-1 is fat mass. The remaining 25-30% is lean mass. This is normal and expected.

2. This ratio can be substantially improved with resistance training and adequate protein. Patients who prioritize strength training see measurably better lean mass preservation.

3. GLP-1 medications preferentially reduce visceral adiposity, the type of fat most strongly linked to metabolic disease and cardiovascular risk.

4. Waist circumference is a practical, free proxy for visceral fat reduction. Track it consistently to see the changes that the scale might not capture.

5. Body composition changes take time. Plan for 3-6 months of consistent training and nutrition to see significant improvements.

6. The metabolic benefit of visceral fat reduction extends beyond weight loss. Visceral fat reduction is associated with improvements in blood pressure, lipid profiles, and inflammation markers (Cleveland Clinic, American Heart Association).

If you have been frustrated by scale weight that does not move while your body composition is improving, or if you want to know exactly what is happening to your fat and lean mass during treatment, a DEXA scan provides objective data. But tracking waist circumference, how your clothes fit, and your strength in the gym are free, practical ways to measure progress.

Your Transformation Health provider and coach are here to help you optimize your body composition outcomes. That is why medical weight loss coaching, resistance training guidance, and nutrition support are included in every program.

Track Your Body Composition

Consider these practical tracking methods over the next 12 weeks:

• Waist circumference: Measure every 2-4 weeks. Target <40 inches (men) or <35 inches (women).
• How your clothes fit: Try on the same pair of jeans or a specific piece of clothing every 4 weeks.
• Strength in the gym: Track weights lifted or reps completed. Progressive improvement signals lean mass preservation.
• Before and after photos: Take them in the same lighting, same pose, every 8 weeks. Visual changes are often clearer than measurements.
• DEXA scan (optional): Baseline before starting, then 6-12 months into treatment. Provides precise fat mass, lean mass, and bone density data.

The goal is not just to see a number on the scale. The goal is to lose fat, preserve muscle, improve your waist circumference and visceral adiposity, and build a body that is stronger, leaner, and metabolically healthier.

That is what body composition optimization looks like.

Citations

[1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

[2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. NEJM. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[3] Smahelova A, Cernikova L, Hill M, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc. 2021;5(Supplement_1):A16. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/

[4] Holm L, Moll T. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options. Eur Heart J. 2023;44(32):3070-3081. https://pmc.ncbi.nlm.nih.gov/articles/PMC10421666/

[5] Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. https://pubmed.ncbi.nlm.nih.gov/27295427/